# A Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors

> **NCT01306630** · PHASE1 · COMPLETED · sponsor: **AVEO Pharmaceuticals, Inc.** · enrollment: 24 (estimated)

## Conditions studied

- Advanced Solid Tumors
- Locally Advanced or Metastatic Breast or Colorectal Cancer

## Interventions

- **DRUG:** tivozanib (AV-951) and capecitabine (Xeloda®)

## Key facts

- **NCT ID:** NCT01306630
- **Lead sponsor:** AVEO Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2014-01
- **Final completion:** 2014-01
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2014-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01306630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01306630, "A Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT01306630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*